FINWIRES · TerminalLIVE
FINWIRES

Gateway Mining Intersects Gold Mineralization at Western Australia Project

By

Gateway Mining (ASX:GML) intersected gold mineralization at its Yandal project in Western Australia during initial first-pass air-core drilling across Celia South and the Great Western Shear Corridor structures, according to a Wednesday filing with the Australian bourse.

Results include 12 meters at 1.4 grams per tonne grade of gold from 60 meters, 10 meters at 2.2 g/t grade of gold from 66 meters, and 16 meters at 1 g/t grade of gold from 104 meters, the filing said.

Additionally, reverse circulation drilling will start in the week of June 15 to focus on depth extensions, per the filing.

Related Articles

Asia

Tata Motors Passenger Vehicles' Total Sales Rise 42% in May

Tata Motors Passenger Vehicles' (NSE:TMPV, BOM:500570) total sales rose 42% to 59,790 units in May, against 42,040 units sold a year ago, according to a Monday filing to the Indian bourses.Total domestic sales in May also grew 42% to 59,090 units from 41,557 units a year earlier, the filing said.Of the total, electric vehicle sales jumped 85% year-on-year to 10,517 units from 5,685 units.

BOM:500570NSE:TMPV
Asia

Dian Tou Energy Acquires Baiyinhua Coal & Power for 11.1 Billion Yuan; Shares Down 4%

Inner Mongolia Dian Tou Energy (SHE:002128) fully acquired Baiyinhua Coal & Power for 11.1 billion yuan, according to a Tuesday disclosure on the Shenzhen bourse.The acquisition was made through share placement and capital injection.The company raised 4.50 billion yuan as part of the acquisition funds.The Chinese coal products maker's shares dropped 4% during the morning trade.

SHE:002128
Asia

Formosa Pharmaceuticals Gets Taiwan's Health Ministry for Pain Relief Drug; Shares Rise 3%

Formosa Pharmaceuticals (TPE:6838) received approval from Taiwan's Ministry of Health and Welfare for a drug to treat inflammation and pain following ocular surgery, according to a Monday Taiwan Exchange filing.Shares gained about 3% in Tuesday's late morning trade.The drug dubbed APP13007, is marketed as BYQLOVI Ophthalmic Suspension 0.05%.Financial details and accumulated development costs were not disclosed.

TPE:6838